Clinical Trial Update: Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Ixazomib in Lupus Nephritis (LN) [Phase 1]

View source ↗

Summary

Phase 1 trial update on rising doses of ixazomib for lupus nephritis focusing on safety, tolerability, and pharmacokinetics; study terminated with results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lupus Nephritis

Drugs mentioned

• ixazomib (ixazomib)

Snippet

Sponsor: Takeda | Conditions: Lupus Nephritis | Phase 1 | Status: TERMINATED | Results posted: 2019-04-08